Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC109-0012 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC109-0012 | DRUG | The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin) |
| placebo | DRUG | The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin) |
Inclusion Criteria: * Czech Republic: Age between 18 - 65 years (both inclusive) * A diagnosis of RA made at least 3 months prior to trial start * Active RA * Methotrexate treatment (between 7.5 mg and 25 mg/week, both inclusive) for at least 12 weeks with a stable dose for at least 4 weeks prior t...
NNC109-0012 is an investigational small molecule being developed for inflammation, specifically studied in active rheumatoid arthritis. It is not approved and remains in clinical development.
NNC109-0012 is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the NYSE under the ticker NVO.
NNC109-0012 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
NNC109-0012 has one completed Phase 2 trial, NCT01282255, which evaluated its efficacy in subjects with active rheumatoid arthritis. The trial enrolled 67 participants across multiple European countries.
No alternative names for NNC109-0012 have been identified. It is referred to solely by this identifier in clinical development.